Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives

Table 2 Efficacy of combination therapy with systemic acting agents and targeted therapy in hepatocellular carcinoma according to current phase I-II studies

Author	Year	Phase	Investigational drug	n	RR	DS	PFS/TTP	PFS-6m (%)	OS
Sun et al[76]	2007	II	Bevacizumab/CapOx	30	11	78	4.5/NR	40	NR
Thomas et al[55]	2009	II	Bevacizumab/erlotinib	40	25	42.5	9.0/NR	NR	15.7
Hsu et al[77]	2008	II	Bevacizumab/capecitabine	45	9	42	4.1/NR	NR	10.7
Zhu et al[78]	2006	II	Bevacizumab/GemOX	33	20	27	5.3/NR	NR	9.6
Berlin et al[79]	2008	II	Bortezomib/doxorubicin	39	2.3	25.6	2.4/NR	NR	5.7
Asnacios et al[80]1	2008	II	Cetuximab/GemOx	45	20	40	4.7/NR	NR	9.5
Louafi et al[81]1	2007	II	Cetuximab/GemOx	35	24	4.5	NR/NR	40	9.2
Knox et al[82]2	2008	II	G3139/doxorubicin	17	0	35	NR/1.8	17.2	5.4
Abou-Alfa et al[83]3	2010	II	Sorafenib/doxorubicin	96	4	77	6.9/8.6	2.7	13.7
Richly et al[84]	2009	I	Sorafenib/doxorubicin	18	6.3	69	4.04/NR	NR	NR

¹Overlap of patient cohorts cannot be excluded from information provided in the abstracts; ²Trial stopped due to lack of efficacy; ³Trial stopped due to superiority of sorafenib;

⁴Calculated from a median duration of disease control rate (combined endpoint for complete and partial response as well as stable disease) of 17.4 wk. CapOx: Capecitabine and oxaliplatin; DS: Disease stabilization (%); GemOx: Gemcitabine and oxaliplatin; NR: Not reported; OS: Overall survival (mo); PFS/TTP: Progression free survival/time to progression (mo); PFS-6m: Progression free survival rate at 6 mo (%); RR: Response rate [complete + partial response (%)].